CMC COMPENDIUM
  • RESIDENCY
    • About CMC
    • Curriculum
    • Benefits
    • Explore Charlotte
    • Official Site
  • FELLOWSHIP
    • EMS
    • Global EM
    • Pediatric EM
    • Toxicology >
      • Tox Faculty
      • Tox Application
    • (All Others)
  • PEOPLE
    • Program Leadership
    • PGY-3
    • PGY-2
    • PGY-1
    • Alumni
  • STUDENTS/APPLICANTS
    • Medical Students at CMC
    • EM Acting Internship
    • Healthcare Disparities Externship
    • Resident Mentorship
  • #FOAMed
    • EM GuideWire
    • CMC Imaging Mastery
    • Pediatric EM Morsels
    • Blogs, etc. >
      • CMC ECG Masters
      • Core Concepts
      • Cardiology Blog
      • Dr. Patel's Coding Blog
      • Global Health Blog
      • Ortho Blog
      • Pediatric Emergency Medicine
      • Tox Blog
  • Chiefs Corner
    • Top 20
    • Current Chiefs
    • Schedules >
      • Conference/Flashpoint
      • Block Schedule
      • ED Shift Schedule
      • AEC Moonlighting
      • Journal Club/OBP/Audits Schedule
      • Simulation
    • Resources >
      • Fox Reference Library
      • FlashPoint
      • Airway Lecture
      • Student Resources
      • PGY - 1
      • PGY - 2
      • PGY - 3
      • Simulation Reading
      • Resident Wellness
      • Resident Research
      • Resume Builder
    • Individualized Interactive Instruction

Laundry Pod Ingestion

3/15/2018

0 Comments

 
Authored by: Dr. Chrissy Zauner
Introduction:
Laundry pod detergents were introduced to the market in the US in 2010. Following this in 2012-2013, the National Poison Data system recorded 17,230 exposures in children younger than the age of 6. The vast majority of ingestions were unintentional due to the candy like design of the pod. Most papers available are case reports, serious outcomes include: superficial partial thickness burns, seizures, respiratory failure requiring intubation. 
Picture
Picture
Recently, there has been a surge in intentional ingestions among teenagers. “Tide Pod Challenge” It remains unclear how it began, possibly stems from an article on The Onion posted December 2015 written from the viewpoint of a child attempting to eat pods. This was followed by a College Humor video about not eating laundry pods in March 2017. Early January 2018, memes started appearing, followed by YouTube videos. 
Between January 1st-January 22nd, there were 86 cases of intentional ingestion. As of Saturday, February 10, 2018 a YouTube search produces 81,200 video results, both of videos performing the challenge and those against it. YouTube recently announced it would be pulling videos due to the dangers of exposure. 
Picture
Picture
Pharmocology/Pharmokinetics: Unclear overall
  • Propylene glycol: absorbed by GI tract, Vd 0.6L/kg, may be absorbed percutaneously through damaged skin areas, 12-45% excreted unchanged in the urine, otherwise metabolized in the liver
    • WHO maximum allowable intake 25 mg/kg
Metabolic Pathways and Active Metabolites:
  • Propylene glycol -> lactaldehyde->lactic acid by alcohol dehydrogenase
    • Then to pyruvate
Toxicity/Mechanism of Toxicity:
  • Much more likely to be symptomatic from pod exposure vs regular detergent. Unclear  whether the significant adverse health effects observed with laundry detergent pod exposures relate to unique ingredients, differences in pH or other chemical properties.
  • Ethoxylated alcohols may cause gastric irritation and lethargy
  • Direct contact may cause irritation of the oropharynx and esophagus
  • Aspiration and resulting pulmonary toxicity may occur with or without coincident CNS
    depression and vomiting
​​Propylene Glycol
  • Cardiovascular: hypotension, bradycardia, widening of the QRS interval, increased T wave amplitude
  • Neurotoxicity: Ethanol and/or PG may contribute to the CNS depression
    o Smaller infants have a decreased ability to clearPG
    o Case studies of seizures in lowbirthweight infants receiving 3g daily in parenteral multivitamins
  • Hyperosmolarity, elevated osmolar gap, metabolic acidosis following metabolism
  • Nephrotoxicity: rental tubular necrosis
  • Is the dose of propylene glycol high enough in Tide Pods to cause significant long term
    damage? Unclear
Clinical Presentation:​
  • Vomiting (most common), aspiration risk?
  • Coughing or choking
  • Respiratory distress
  • Altered mental status
  • Seizure-like activity
  • Eye irritation
  • Skin irritation 
Picture
Treatment:
  • Topical exposure: Irrigation
  • Ingestion: Supportive care, airway protection, IVF, oxygen 

​

References:
  • Beuhler MC, Gala PK, Wolfe HA, Meaney PA, Henretig FM a case series and discussion of recent literature. Pediatr Emerg Care. 2013;29(6):743–747. 
  • Bever, L. Teens are daring each other to eat Tide pods. We don't need to tell you that's a bad idea. The Washington Post. January 17, 2018. https://www.washingtonpost.com/news/to-your- health/wp/2018/01/13/teens-are-daring-each-other-to-eat-tide-pods-we-dont-need-to-tell- you-thats-a-bad-idea/?utm_term=.fea447dea690. Accessed February 12, 2018
  • Centers for Disease Control and Prevention (CDC). Health hazards associated with laundry detergent pods. United States, May-June 2012. MMWR. 2012;61:825Y829.
  • HERA. Alcohol Ethoxylates. Human & Environmental Risk Assessment on ingredients of European household cleaning products. September 2009. Available at: http://www.heraproject.com/files/34-F-09%20HERA% 20AE%20Report%20Version%202%20- %203%20Sept%2009.pdf. Accessed February 12, 2018.
  • Proctor and Gamble. MSDS: Tide Pods. https://www.pg.com/productsafety/msds/2014/Tide%20Pods%20MSDS%20July%202014.pdf Accessed Februrary 12, 2018
  • Proctor and Gamble. SDS: Tide. https://www.pgproductsafety.com/productsafety/sds/SDS_2016/Tide.pdf. Accessed February 12, 2018.
  • Schneir, A, Rentmeester, L, Clark, R, Canterll, FL. Toxicity Following Laundry Detergent Pod Ingestion. Pediatric Emergency Care. 2013 June; 29(6):741-742. . Laundry detergent “pod” ingestions:
  • Valdez AL, Casavant MJ, Spiller HA, Chounthirath T, Xiang H, Smith GA. Pediatric exposure to laundry detergent pods. Pediatrics. 2014 Dec;134(6):1127-35. 


0 Comments

Artemether Lumefantrine

3/2/2018

0 Comments

 
Authored by Dr. Enola Okonkwo
 
Introduction
Artemether Lumefantrine is an oral medication which is used in treatment of chloroquine resistant uncomplicated malaria.  Artemether Lumefantrine falls within the drug class of Artemisinin-based combination therapies which have been found to be highly effective in treating malaria and are substantially less toxic than quinoline antimalarials.  Artemisins are derived from a Chinese medicinal herb which comes from the sweet wormwood plant (1).   Artemether Lumefantrine, known by the brand name Coartem, is the most widely used artemisinin based combination therapy used in Africa and is one of three medications recommended by the CDC as first line oral treatment for uncomplicated falciparum malaria within the United States (2). 

Structure
Picture
​1 tablet = 20mg artemether and 120 mg lumefantrine. 
Dosing is weight based.  For patients > 35 kg they are taking 4 tablets per dose twice daily for 3 days. 
 
Pharmacology/Pharmacokinetics:
Absorption/Distribution/Metabolism/Excretion
 
Artemeter is rapidly absorbed.  Peak plasma level of artemeter is approximately 2 hours. The half-life after ingestion is 2 hours (4-5). 95% of artemether is protein bound but quickly undergoes metabolism to dihydroartemisin which is approximately 50% protein bound.  Half life of dihydroartemisin is also around 2 hours (5). Bioavailability increased 2-3 fold when consumed with food (4).
 
Lumefantrine – Initial absorption at approximately 2 hours. Peak plasma level approximately 6-8 hours.    Half life is 4-5 days.  It is highly protein bound and has a large volume of distribution.  High fat meals significantly increase absorption 16 fold (4). 
   
 
Significant Drug/Drug interactions
Numerous theoretic drug interactions have been reported.  However, there is scant data available reporting clinical effects of drug interactions.
-May enhance QTc prolonging effects
-May enhance toxic effects of other antimalarial or HIV medications
-May increase serum concentration of antipsychotics
-May decrease serum concentration of estrogen related contraceptives
-May decrease serum concentration of CYP3A4 Substrates
 
Metabolic Pathways and active metabolites
 
Arthemeter is metabolized by the liver to the active metabolite dihydroartemisinin primarily by CYP3A4/5. 
 
Lumefantrine is metabolized by the liver to desbutyl-lumefantrine by CYP3A4. 
 
Studies suggest that artemisins inhibit the sarco/endoplasmic reticulum Ca ATPases of the malaria parasite causing rapid reduction in the parasite (6-7).  The mechanism of lumefantrine is unknown but both agents inhibit nucleic acid and protein synthesis.  Artemether rapidly kills the majority of the parasite and lumefantrine goes on to kill the residual remaining parasite (4-5). 
 
Mechanism of Toxicity
 
Artemether Lumefantrine has been extensively used for the treatment of malaria and appears to have an excellent safety profile.  There are no reported overdoses or intentional ingestions.  There has been no evidence of significant systemic or local toxicity reported in any large human study (1, 20-21).  However, there is animal data and a few small human studies and case reports which suggest neurotoxicity and QT prolongation are possible toxic effects of artimisinins (14). 
 
Neurotoxicity was especially common in animal studies both clinically and histologically (8-10, 14).  In vitro studies have postulated that neurotoxicity results secondary to ATP depletion of neurons and free radical generation created by the breakdown of artemisins (Schmuck 2002, Smith 1998) . Toover et. el wrote a review article cautioning that neurotoxic effects may also occur in humans more frequently than previously thought, though many critics viewed their review as bias (8, 13).  There are a small number of case reports within humans suggesting that artemisins contributed to neurologic symptoms such as anxiety, tremor, and ataxia (8, 15-16).  A small study looking at construction workers treated with arthemeter suggested that individuals had hearing loss following the administration of artemether (17).  Obviously, this study is limited by a serious potential confounder and attempts to reproduce these results have failed (18). 
 
One case report of delayed hemolytic anemia, not thought to be related to malaria was reported (19).
 
Clinical Toxicity
 
Given patients taking artemether lumefantrine have malaria, it is difficult to distinguish between symptoms caused by the disease state of malaria versus symptoms which may be attributed to medication toxicity.  Clinical toxicity appears to be very rare or possibly underreported.  A large review of 188 studies including over 9,000 patients found no serious clinical toxicity (21). This review article used methodology similar to Cochrane review and reported transient neutropenia in 1.3%, reticulocytopenia (0.6%), elevated liver enzymes (0.9%), and transient bradycardia and prolonged QT (1.1%).  The most common side effects reported were gastrointestinal.  The authors conclude that Artemether Lumefantrine is a safe and efficacious drug. 
 
Common adverse events (4, 20-21)
Abdominal pain
Anorexia
Vomiting
Diarrhea
Headache
dizziness.
Pruritis and Rash < 2%
 
Laboratories
No specific toxicology labs are available
 
Management of Toxicity
No accepted recommendations regarding toxicity given the scarcity of data suggesting toxicity.
Below are general recommendations based off of literature review:
Avoid concurrent use of additional antimalarial medications
Use caution administering additional drugs which can prolong QT
Use caution in hypokalemia and replete electrolytes as needed
Use caution in patients with prolonged QT
Obtain EKG as screening for arrhythmia
 
References:
 
1.  Hien, T. T., White, N. J., & White. (1993). Qinghaosu. The Lancet, 341(8845), 603–608. https://doi.org/10.1016/0140-6736(93)90362-K
 
2. Center for Disease Control. (2009). Guidelines for treatment of malaria in the United States. Treatment Table Update, May, (770), 855–857. Retrieved from http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Guidelines+for+Treatment+of+Malaria+in+the+United+States#1
 
3.  Amin, N. C., Fabre, H., Blanchin, M.-D., Montels, J., & Aké, M. (2013). Determination of artemether and lumefantrine in anti-malarial fixed-dose combination tablets by microemulsion electrokinetic chromatography with short-end injection procedure. Malaria Journal, 12, 202. https://doi.org/10.1186/1475-2875-12-202
 
4.  Waning, B., & Montange, M. (2015). Access Pharmacy. Retrieved from http://accesspharmacy.mhmedical.com/content.aspx?bookid=438&sectionid=40428529
 
5.  White, N. J., Van Vugt, M., & Ezzet, F. (1999). Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clinical Pharmacokinetics. Adis International Ltd. https://doi.org/10.2165/00003088-199937020-00002
 
6.  Krishna, S., Pulcini, S., Moore, C. M., Teo, B. H. Y., & Staines, H. M. (2014, January). Pumped up: Reflections on PfATP6 as the target for artemisinins. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2013.10.007
 
7.  Eckstein-Ludwig, U., Webb, R. J., Van Goethem, I. D. A., East, J. M., Lee, A. G., Kimura, M., … Krishna, S. (2003). Artemisinins target the SERCA of Plasmodium falciparum. Nature, 424(6951), 957–961. https://doi.org/10.1038/nature01813
 
8.  Toovey, S. (2006, October 10). Are currently deployed artemisinins neurotoxic? Toxicology Letters. https://doi.org/10.1016/j.toxlet.2006.06.001
 
9.  Genovese, R. F., Newman, D. B., Li, Q., Peggins, J. O., & Brewer, T. G. (1998). Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Research Bulletin, 45(2), 199–202. https://doi.org/10.1016/S0361-9230(97)00339-0
 
10.  Petras, J. M., Young, G. D., Bauman, R. A., Kyle, D. E., Gettayacamin, M., Webster, H. K., … Brewer, T. G. (2000). Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: The lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anatomy and Embryology, 201(5), 383–397. https://doi.org/10.1007/s004290050326
11.  Schmuck, G., Roehrdanz, E., Haynes, R. K., & Kahl, R. (2002). Neurotoxic mode of action of artemisinin. Antimicrobial Agents and Chemotherapy, 46(3), 821–827. https://doi.org/10.1128/AAC.46.3.821-827.2002
 
12.  Smith, S. L., Maggs, J. L., Edwards, G., Ward, S. A., Park, B. K., & McLean, W. G. (1998). The role of iron in neurotoxicity: a study of novel antimalarial drugs. Neurotoxicology, 19(4–5), 557–559.
 
13.  Toovey, S. (2006, October 10). Are currently deployed artemisinins neurotoxic? Toxicology Letters. https://doi.org/10.1016/j.toxlet.2006.06.001
 
14.  Brewer, T. G., Peggins, J. O., Grate, S. J., Petras, J. M., Levine, B. S., Weina, P. J., … Schuster, B. G. (1994). Neurotoxicity in animals due to arteether and artemether. Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 33–36. https://doi.org/10.1016/0035-9203(94)90469-3
 
15.  Miller, L. G., & Panosian, C. B. (1997). Ataxia and slurred speech after artesunate treatment for falciparum malaria. New England Journal of Medicine, 336(18), 1328. https://doi.org/10.1056/NEJM199705013361818
 
16.  Franco-Paredes, C., Dismukes, R., Nicolls, D., & Kozarsky, P. E. . (2005). Neurotoxicity Due to Antimalarial Therapy Associated with Misdiagnosis of Malaria. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 40(11), 1710–1711. https://doi.org/10.1086/430180
 
17.  Toovey, S. (2006). A case-control auditory evaluation of patients treated with artemether-lumefantrine. American Journal of Tropical Medicine and Hygeine 74, 939-940. 
 
18.  Hutagalung, R., Htoo, H., Nwee, P., Arunkamomkiri, J., Zwang, J., Carrara, V. I., … Nosten, F. (2006). A case-control auditory evaluation of patients treated with artemether-lumefantrine. American Journal of Tropical Medicine and Hygiene, 74(2), 211–214. https://doi.org/74/2/211 [pii]
 
19.  Hasegawa, C., Kudo, M., Maruyama, H., Kimura, M. (2017). Severe delayed haemolytic anaemia associated with artemether-lumefantrine treatment of malaria in a Japanese traveler. Journal of Infection and Chemotherapy.  In press.  https://doi.org/10.1016/j.jiac.2017.10.008
 
20.  Alkadi, H. O. (2007, November). Antimalarial drug toxicity: A review. Chemotherapy. https://doi.org/10.1159/000109767
 
21.  Ribeiro, I. R., & Olliaro, P. (1998). Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Medecine Tropicale : Revue Du Corps de Sante Colonial, 58(3 Suppl), 50–53. Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=10212898
 
 
 
0 Comments

ADHD Medications and Stuttering?

3/2/2018

0 Comments

 
Authored by Dr. Kyle Roedersheimer
Introduction to ADHD
  • ADHD is the most well-known and researched neurodevelopmental disorder of childhood
  • Approximately 5-6% of children and 2-3% of adults
  • Both genetic and environmental factors are implicated
  • The genes that are thought to code for ADHD are involved in the heritability of autism spectrum disorders and Tourette’s disorder
  • In general, there are three types of ADHD; Inattentive, Hyperactive and Combined
 
History of Amphetamines
  • First synthesized in 1887 and then first marketed in 1932 as a nasal decongestant
  • Both amphetamine and methamphetamine were supplied as stimulants for soldiers and prisoners of war in WW II
  • In the 1970s FDA made amphetamines schedule II and use declined
  • However, increased use with derivatives methamphetamines and MDMA
Amphetamines
  • Phenylethylamine is any structure with an ethyl group backbone that has an aromatic group and a terminal amine
  • Specific substitutions made to the Phenylethylamine backbone have led to the wide variety of novel amphetamines
  • Large-group substitution at the alpha carbon reduces the stimulant and cardiovascular effects but retains the anorectic properties
  • Substitution at the para position of the phenyl ring enhances the hallucinogenic or serotonergic effects
Picture
Psychostimulants
  • Phenylethylamine derivatives have become popular over the past 20 years in the treatment of ADHD
  • The psychostimulants methylphenidate, dexmethylphenidate, lisdexamfetamine or amphetamine salts are most effective
  • Alpha 2-adrenergic agonists such as extended release preparations of guanfacine and clonidine are less effective 
Picture
Picture
Mechanism of action
  • Enter the nerve cell by either passive diffusion or exchange diffusion through reuptake transporter that is dose dependent
  • Low concentrations, amphetamines release dopamine from cytoplasmic pool
  • Moderate concentrations, amphetamines diffuse through the presynaptic terminal membrane and interact with the neurotransmitter transporter on the vesicular membrane to cause exchange release of dopamine into the cytoplasm
  • High concentrations, amphetamines diffuse through the cellular and vesicular membranes
  • They also block the reuptake of catecholamines by competitive inhibition and also thought to be weak monoamine oxidase inhibitors
Action at noradrenergic nerve ending –
1,2 – activating or antagonizing postsynaptic alpha and beta adrenoceptors
3 – Amphetamines release dopamine from the cytoplasmic pool by exchange diffusion at the dopamine uptake transporter site in the membrane
4 – amphetamines diffuse through the presynaptic terminal membrane and interact with the neurotransmitter transporter on the vesicular membrane to cause exchange release of dopamine into the cytoplasm, dopamine is subsequently release into the synapse by reverse transport at the dopamine uptake site
5 – amphetamine diffuses through the cellular and vesicular membranes, alkalinizing the vesicles, and permitting dopamine release from the vesicles and delivery into the synapse by reverse transport
​6  – inhibiting monoamine oxidase
Picture
Pharmacology/Pharmacokinetics:
  • Absorption/Distribution/Metabolism/Excretion
    • Absorption – all are rapidly absorbed, with bioavailability that ranges between 60% and 90% depending on the route of administration, peak serum concentrations between 3-6 hours
    • Distribution – most compartments of the body, most are relatively lipophilic and readily cross the BBB, Vd from 3-33 L/kg depending on the substance
    • Metabolism – all are metabolized in the liver, however, the pathway depends on the specific substance, most involve CYP2D6
    • Excretion – renal elimination of the parent compound is substantial, also acidification of the urine can increase elimination, but usually not recommended
 
Therapeutic levels
  • Not generally obtained given lack of clinical relevance
 
Significant Drug/Drug Interactions
  • MAOI use, as well as linezolid or methylene blue may cause hypertensive crisis
 
Metabolic Pathways and active metabolites
  • Depending on the amphetamine, many active metabolites can be formed
  • Dealkylation and demethylation are mainly performed by CYP1A2, CYP2D6 and CYP3A4, also performed by flavin monooxygenase
Toxicity/Clinical Presentation
  • Doses >/= 1mg/kg have been known to cause acute toxicity
  • Uncontrolled hyperadrenergic state including excess serotonin, dopamine and norepinephrine
  • Things that will kill you? à dysrhythmias, seizures and hyperthermia
  • Things to worry about? à myocardial ischemia and infarction, rhabdomyolysis, metabolic acidosis
  • MDMA specifically you worry about hyponatremia related seizures
Picture
Diagnostic Testing and Laboratories
  • Chem 8, EKG and cardiac monitoring/observation for at least 6 hours, depending on presentation
  • Can obtain UDS to assess presence of amphetamines, however, clinical exam and history is key
    • Many immunoassays have high rate of false positives and false negatives
    • Many substances are similar to amphetamines and may cross-react with the immunoassay
    • False negatives may occur with MDMA and cathinones
  • Can consider further testing including but not limited to CBC, UA, CPK, coagulation studies, CXR, CT scan of the head and LP depending on clinical situation
 
Treatment/Management
  • As with all presentations, manage ABCs and gain IV access and place patient on monitor
  • Vital signs, rapid glucose and complete physical exam, importantly quickly obtain internal temperature
  • Hyperthermia requires rapid external and even potentially internal cooling
  • Benzodiazepines are first line for both agitation and hypertension/tachycardia
  • If hypertension persists and you have attempted to control agitation with benzos, can considering a-adrenergic antagonists like phentolamine and peripheral vasodilators like nitroprusside and nitroglycerin
  • Use antipsychotics with caution, have not been shown to be as effective as benzos and may lower seizure threshold, alter temperature regulation, cause acute dystonia and precipitate cardiac dysrhythmias
  • If concerned for rhabdomyolysis, maintain UOP of at least 1-2 mL/kg/h
  • Need to be suspicious for body packers and stuffers with these substances, treat accordingly
 
What is Stuttering? What causes it?
  • Condition in which the normal pattern, rhythm, or timing of speech is disrupted, may be characterized by repetition and prolongation of words, phrases, and sounds, as well as hesitations or pauses that interrupt speech flow
  • Can be developmental, psychogenic, result of a medication effect and secondary to brain injuries
 
Multiple Case Reports Discussing Stuttering Associated with ADHD Medications
  • A 1991 case report of a 3 year old with two separate trials of stimulants, each of which resulted in stuttering
    • 2.5 mg BID methylphenidate and then pemoline 9.375 mg
    • After 18 months, no recurrence of stuttering
    • They hypothesized that stuttering a result of increased dopaminergic neurotransmission
  • A 2015 case report of a 7 year old trialed on methylphenidate and developed stuttering
    • previously healthy with no family or personal history of speech difficulty or stuttering
    • diagnosed with ADHD and started on 10mg daily of methylphenidate
    • 10 days later developed stuttering, decided to stop medication, and stuttering gone in 7 days
    • They noted that methylphenidate had even been used to treat stuttering in previous cases
    • Case report from 1996 reporting sertraline induced stuttering
      • Sertraline was discontinued, and stuttering stopped
      • Akathisia has been noted to be induced by sertraline and this could be potentially related to serotonergic inhibition of the dopaminergic neurons whose cell bodies are located in the ventral tegmental area versus serotonergic inhibition of the dopamine pathways in the nigrostriatum
      • Needs more research whether this is related to speech abnormalities 
Do ADHD medications cause stuttering?
  • Some studies show that hyperdopaminergic status of the brain provokes stuttering
  • The symptoms of stuttering are compared with basal ganglia motor disorders like Parkinson’s disease and dystonia
  • It is proposed that the basal ganglia-thalamocortical motor circuits through the putamen are likely to play a key role in stuttering
  • The core dysfunction in stuttering is suggested to be impaired ability of the basal ganglia to produce timing cues for the initiation of the next motor segment in speech​
Picture
  • Similarities between stuttering and dystonia are indicated and can possibly be related to the dopamine system
  • A study in a bird model did show a relationship to amphetamine administration and their songs
    • Amphetamine administration increased the stereotypy of syllable structure and sequencing as well as vocal motor repetition
    • Amphetamine increased the degree to which stereotyped sequences of syllables were completed before song determination
    • Dopaminergic activity in cortical and basal ganglia structures found to be elevated in stuttering
​
References
  1. Alm PA. Stuttering and the basal ganglia circuits: A critical review of possible relations. Journal of communication disorders. 07/2004;37(4):325-369. doi: 10.1016/j.jcomdis.2004.03.001.
  2. Alpaslan AH. Stuttering associated with the use of short-acting oral methylphenidate. Journal of clinical psychopharmacology. 12/2015;35(6):739-741. doi: 10.1097/JCP.0000000000000403.
  3. Burd L. Stuttering and stimulants. Journal of clinical psychopharmacology. 02/1991;11(1):72-73.
  4. Christensen RC. A case of sertraline-induced stuttering. Journal of clinical psychopharmacology. 02/1996;16(1):92-93.
  5. Dopheide JA, Pliszka SR. Attention Deficit/Hyperactivity Disorder. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill; . http://accesspharmacy.mhmedical.com.libproxy.lib.unc.edu/content.aspx?bookid=1861&sectionid=146063877. Accessed February 19, 2018.
  6. Jang DH. Amphetamines. In: Hoffman RS, Howland M, Lewin NA, Nelson LS, Goldfrank LR. eds. Goldfrank's Toxicologic Emergencies, 10e New York, NY: McGraw-Hill; 2015. http://accesspharmacy.mhmedical.com.libproxy.lib.unc.edu/content.aspx?bookid=1163&sectionid=65097893. Accessed February 19, 2018.
  7. Matheson LE. Catecholaminergic contributions to vocal communication signals. The European journal of neuroscience. 05/2015;41(9):1180-1194. doi: 10.1111/ejn.12885.
  8. Rabaeys H. Influence of methylphenidate on the frequency of stuttering: A randomized controlled trial. The Annals of pharmacotherapy. 10/2015;49(10):1096-1104. doi: 10.1177/1060028015596415.
 

0 Comments

Proton PUmp Inhibitors and risk of STroke

3/1/2018

0 Comments

 
Authored By: Meredith Binford
Background:
Proton pump inhibitors (PPIs) inhibit H+K+ATPase proton pumps in the stomach to reduce acid excretion. Among the most frequently prescribed drugs worldwide and are generally well tolerated. Now they are available for long-term use without medical supervision. Often prescribed to circumvent GI side effects from dual antiplatelet agents used for cardiovascular disease secondary prevention. However recent observational studies have linked PPI use to increased cardiovascular risk (MI and stroke) even in patients not taking antiplatelet agents.


Mechanism:
-impair lysosomal acidification and enzyme activity
-accelerate telomere erosion
-speed endothelial aging as manifested by impaired cell perforation and angiogenesis -impair the NO synthase pathway though asymmetric dimethylarginine (ADMA) 
​
Picture


**PPIs inhibit the enzyme that degrades ADMA therefore inhibiting more nitric oxidase which is vasoprotective 

​

3 recent articles investigate PPIs and risk of stroke:

1. A large retrospective study from the Taiwan National Health Insurance Database studied whether PPI use alone could be associated with first time ischemic stroke. In a propensity score matched analysis (400,000 patients) over 120 days PPI use was associated with a higher risk of hospitalization due to ischemic stroke with hazard ratio of
1.36 (95% CI 1.14-1.62, P=0.001). In subgroup analysis, the risk was more prominent in those less than 60 years of age but gender, prior MI, diabetes, hypertension, use of antiplatelet agents or NSAIDs, or types of PPI did not have an influence on the risk. In the nested case-control analysis (30,000 patients), the adjusted odds ratios for PPI use were 1.77 (95% CI 1.45-2.17, P<0.001) within 30 days and 1.65 (95% CI 1.31-2.08, P<0.001) 31 to 90 days before ischemic stroke. The proportions of H2 blocker users and non users were comparable before the event. One of the major arguments against the association is confounding by indication for PPI use as PPIs are used over H2 blockers in the presence of more severe acid related GI disorders. Other uncorrected confounders include obesity, lack of exercise, smoking, compliance with hypertension treatment, diabetes, hyperlipidemia, other medical illnesses. Also limited by 120 day follow up which may have masked confounders of PPI use.

2. Danish registry of people who underwent elective EGD (215,000 patients) was analyzed in a time varying design to asses dose response effects on hazard ratios as well as in a baseline treatment design to show impact of long term use on risks of first time stroke and MI. Current PPI exposure was associated with significantly higher rates of both ischemic stroke with hazard ratio of 1.13 (95% CI 1.08-1.19) and MI with hazard ratio of 1.31 (95% CI 1.23-1.39) after adjusting for age, sex, comorbidities and concomitant medications. High dose PPI was associated with increased rates of ischemic stroke with hazard ratio of 1.31 (95% CI 1.21-1.42) and MI with hazard ratio of 1.43 (95% CI 1.30-1.57). H2 blockers were not significantly associated with ischemic stroke or MI. Long-term PPI users had a 29% greater absolute risk of ischemic stroke and a 36% greater absolute risk of MI within six months period. One limitation is confounding that PPI identifies unhealthy individuals. When estimating impact of smoking habit, obesity, and exercise the net confounding bias was between 3.8 and 4.1% which reduced the hazard ratio to 1.08 for ischemic stroke and 1.26 for MI. Also concern of a lead in bias as subjects were likely exposed to PPI therapy before EGD. 

3. Analysis from the Nurses Health Study and the Health Professionals Follow Up Study (950,000 person years) observed an association between regular PPI use and risk of ischemic stroke in age-adjusted models and multivariate models adjusting for known risk factors for ischemic stroke that was consistent with findings of prior reports. However additional adjustment for factors that may be associated with initiation and continuation of PPI therapy including history of peptic ulcer disease, GERD, GI bleeding and prior H2 blocker use
substantially attenuated the association. They found that participants who were regular PPI users at baseline tended to have higher rates of chronic medical conditions including prior history of hypertension, hyperlipidemia, CAD, diabetes, as well as lower levels of physical activity expenditure. Among women, regular PPI users were more likely to have a higher BMI and a prior history of menopausal hormonal use. Association of PPI use with ischemic stroke may be due to residual confounding by factors associated with the indication for PPI use, for example metabolic syndrome. 


Conclusion:
There is a plausible biological mechanism to explain the association of PPIs with increased cardiovascular risk. Large retrospective studies show association especially with longer use and higher dose PPI. However there is concern of confounding as may be related to more unhealthy patients using PPIs. 


References:

Sehested, TSG et al. Long term use of proton pump inhibitors, dose-response relationship and associated risk of scheming stroke and myocardial infarction. Journal Internal Medicine 2017, doi: 10.1111/joim.12698.
Nguyen LH, Lochhead P, Joshi AD, Cao Y, Ma W, Khalili H, Rimm EB, Rexrode KN< Chan AT. No significant association between proton pump inhibitor use and risk of stroke after adjustment for lifestyle factors and indication. Gastroenterology 2018, doi: 10.1053/j.gastro.2017.12.006. Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S- J. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol 2017; 112: 1– 10.
Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accel- erate endothelial senescence. Circ Res 2016; 118: e36–42.
Ghebremariam YT, Lependu P, Lee JC et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128: 845–53.
Cooke JP. Asymmetrical dimethylarginine: the u€ber marker? Circulation 2004; 109: 1813–9. 

0 Comments

Soursop

3/1/2018

0 Comments

 
Authored by Dr. Natalie Wood
Picture
Soursop is the fruit of the evergreen tree, Annona muricata . This tree is native to tropical regions in the South and Central America. Often used in foods, also widely advertised as an anticancer agent. 

Uses: 
-The flesh of the fruit consists of an edible, white pulp , some fiber, and a core of indigestible, black seeds. Used in foods
-eaten as dessert
-smoothies, fruit juice drinks -candy
-sorbets and ice cream flavoring

-Traditional medicinal uses for diarrhea, liver disease, heart disease, intestinal parasites, diabetes, and cancer. -Pesticides, insecticides and topical insect repellant in latin america
-shampoos for treating lice and ticks 

Toxic component: Annonacin
-Acetogenin -characterized by a long aliphatic chain of 35 to 38 carbons bonded to a γ-lactone α ring, terminally substituted by β-unsaturated methyl, with one or two tetrahydrofurans (THF) located along the hydrocarbon chain.
-It’s structure makes it highly lipophilic and able to cross membranes easily and cross into nerve cells
​-Caparros-Lefebvre and Elbaz (1999) reported in Guadeloupe, atypical parkinsonism was abnormally frequent, and represented 75% of progressive parkinsonism while Parkinson’s disease accounted for only 25% of the cases. 

Picture

-This is exceptionally frequent compared to epidemiological data from European countries where atypical parkinsonism accounts for only approximately 5% of all cases
- A higher proportion of patients with atypical parkinsonism (consumed soursop fruit 97%; consumed herbal tea 83%) than patients with Parkinson’s disease (fruit 59%; herbal tea 18%) or control with no Parkinson symptoms (fruit 60%; herbal tea 43%).
-When directly injecting rats for one month with the estimated amounts of annonacin ingested in a year by eating one fruit daily, this induced neurodegeneration in the basal ganglia and mesencephalon (Champy et al., 2004) -As an indication of its potential toxicity, an adult who consumes one fruit or can of nectar a day is estimated to ingest over 1 year the amount of annonacin that induced brain lesions in rats receiving purified annonacin by intravenous infusion.
-Multiple studies showing toxicity in vitro to dopaminergic neurons
-Cultured neurons treated with low doses of annonacin exhibit hallmarks of tauopathy, including increased tau concentration, tau hyperphosphorylation, cell death and somatodendritic redistribution of hyperphosphorylated tau which is that same pathophysiology of progressive supranuclear palsy.
-Studied as a cytotoxic agent for use in cancer chemotherapy
-Extract from the seeds and leaves have IC50 comparable to doxorubicin at .57μg/mL (seed) and .36μg/mL (leaves) compared to .11μg/mL (doxorubicin) in leukemia cells.
-Mechanism of action is via annonacin, the acetogenin causing mitochondrial membrane potential disruption. It inhibits NADH dehydrogenase on Complex I of the electron transport chain. Creates reactive O2 species that can damage DNA and other components of mitochondria
-Annona muricata leaf extract reduced the tumor's size and weight, showed anti-metastatic features, and induced apoptosis in vitro and in vivo of the 4 T1 breast cancer cell lines. Furthermore, it decreased the level of nitric oxide and malondialdehyde in tumor while also increased the level of white blood cell, T-cell, and natural killer cell population. 


​
Picture

Pharmacology
-LD 50 >2g/kg
-In IV administration to Rats 3800 and 7600 μg/kg daily caused neurodegeneration over a period of 28 days -it appears that chronic consumption causes the neurodegeneration
​
Presentation
-Levodopa resistant parkinsonism similar to progressive supranuclear palsy
-PSP presents with loss of balance, bradykinesia, rigidity, problems controlling eye movements, issues with speech and swallowing
-Patients in Guadaloupe:
-early postural instability
-supranuclear oculomotor dysfunction
-greater frequency of patients with tremor as compared to typical PSP
-greater frequency of patients with hallucinations as compared to typical PSP

Laboratories
-no laboratory evidence of annonacin toxicity
-annonacin can be identified in brain neurons on autopsy

Treatment/Management
-stop ingestion of soursop
-poor response to levodopa or other parkinson’s treatment agents 

​

Resources
Caparros-Lefebvre, Dominique, Nicolas Sergeant, Andrew Lees, Agnes Camuzat, Susan Daniel, Annie Lannuzel, Alexis Brice, Eduardo Tolosa, Andre Delacourte, and Charles Duyckaerts. "Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy." Brain 125.4 (2002): 801-11. Web. 9 July 2017.
Champy, Pierre, Alice Melot, Vincent Guérineau Eng, Christophe Gleye, Djibril Fall, Gunter U. Höglinger, Merle Ruberg, Annie Lannuzel, Olivier Laprévote, Alain Laurens, and Reynald Hocquemiller. "Quantification of acetogenins inAnnona muricata linked to atypical parkinsonism in guadeloupe."
Movement Disorders 20.12 (2005): 1629-633. Web. 9 July 2017.
Clement, Yuri N., Varune Mahase, Annelise Jagroop, Kelly Kissoon, Aarti Maharaj, Prashant Mathura, Chrys Mc Quan, Divya Ramadhin, and Cherrista Mohammed. "Herbal remedies and functional foods used by cancer patients attending specialty oncology clinics in Trinidad." BMC Complementary and Alternative Medicine 16.1 (2016): n. pag. Web. 09 July 2017.
Coria-Téllez, Ana V., Efigenia Montalvo-Gónzalez, Elhadi M. Yahia, and Eva N. Obledo-Vázquez. "Annona muricata: A comprehensive review on its traditional medicinal uses, phytochemicals, pharmacological activities, mechanisms of action and toxicity." Arabian Journal of Chemistry (2016): n. pag. Web. 9 July 2017.
Esposti, M. Degli, A. Ghelli, M. Ratta, D. Cortes, and E. Estornell. "Natural substances (acetogenins) from the familyAnnonaceaeare powerful inhibitors of mitochondrial NADH dehydrogenase (Complex I)."
Biochemical Journal 301.1 (1994): 161-67. Web. 9 July 2017.
Kuete, Victor, Joachim K. Dzotam, Igor K. Voukeng, Aimé G. Fankam, and Thomas Efferth. "Cytotoxicity of methanol extracts of Annona muricata, Passiflora edulis and nine other Cameroonian medicinal plants towards multi-factorial drug-resistant cancer cell lines." SpringerPlus 5.1 (2016): n. pag. Web.
Salama, Mohamed, and Oscar Arias-Carrión. "Natural toxins implicated in the development of Parkinson’s disease." Therapeutic Advances in Neurological Disorders 4.6 (2011): 361-73. Web. 9 July 2017.
Lannuzel, A., G. U. Hoglinger, S. Verhaeghe, L. Gire, S. Belson, M. Escobar-Khondiker, P. Poullain, W. H. Oertel, E. C. Hirsch, B. Dubois, and M. Ruberg. "Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?"
Brain 130.3 (2007): 816-27. Web. 9 July 2017.
Soursop . N.p., n.d. Web. 09 July 2017. 

0 Comments

    Toxicology Blog

    Picture

    Author

    EM Rotators on Toxicology

    Selected by Feedspot as one of the Top 20 Toxicology Blogs on the web
    Subscribe to Tox Blog Emails

    Archives

    March 2018
    November 2017
    October 2017
    August 2017
    April 2016
    November 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015

    Categories

    All
    Bath Salts
    Domoic Acid
    Etomidate
    Herbals
    Intralipid Therapy
    Mercury
    Overdose
    Precedex
    Propofol
    SSRI

    Disclaimer: All images included on this blog are the sole property of CMC EM Residency and cannot be used or reproduced without written permission.  Patient identifiers have been redacted/changed or patient consent has been obtained.  Information contained in this blog is the opinion of the author and application of material contained in this blog is at the discretion of the practitioner to verify for accuracy.

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • RESIDENCY
    • About CMC
    • Curriculum
    • Benefits
    • Explore Charlotte
    • Official Site
  • FELLOWSHIP
    • EMS
    • Global EM
    • Pediatric EM
    • Toxicology >
      • Tox Faculty
      • Tox Application
    • (All Others)
  • PEOPLE
    • Program Leadership
    • PGY-3
    • PGY-2
    • PGY-1
    • Alumni
  • STUDENTS/APPLICANTS
    • Medical Students at CMC
    • EM Acting Internship
    • Healthcare Disparities Externship
    • Resident Mentorship
  • #FOAMed
    • EM GuideWire
    • CMC Imaging Mastery
    • Pediatric EM Morsels
    • Blogs, etc. >
      • CMC ECG Masters
      • Core Concepts
      • Cardiology Blog
      • Dr. Patel's Coding Blog
      • Global Health Blog
      • Ortho Blog
      • Pediatric Emergency Medicine
      • Tox Blog
  • Chiefs Corner
    • Top 20
    • Current Chiefs
    • Schedules >
      • Conference/Flashpoint
      • Block Schedule
      • ED Shift Schedule
      • AEC Moonlighting
      • Journal Club/OBP/Audits Schedule
      • Simulation
    • Resources >
      • Fox Reference Library
      • FlashPoint
      • Airway Lecture
      • Student Resources
      • PGY - 1
      • PGY - 2
      • PGY - 3
      • Simulation Reading
      • Resident Wellness
      • Resident Research
      • Resume Builder
    • Individualized Interactive Instruction